Communiqués de presse

21 janvier 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

21 janvier 2020

ACTICOR BIOTECH INTEGRE LE 1ER FRENCH TECH 120

Communiqués de presse

21 janvier 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Communiqués de presse

21 janvier 2020

ACTICOR BIOTECH INTEGRE LE 1ER FRENCH TECH 120

Communiqués de presse

21 janvier 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Communiqués de presse

21 janvier 2020

ACTICOR BIOTECH INTEGRE LE 1ER FRENCH TECH 120

Communiqués de presse

6 novembre 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Communiqués de presse

6 novembre 2019

ACTICOR BIOTECH LEVE 7 M € SUPPLEMENTAIRES POUR COMPLETER SA SERIE B A HAUTEUR DE 22,3 M €

Communiqués de presse

6 novembre 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Communiqués de presse

6 novembre 2019

ACTICOR BIOTECH LEVE 7 M € SUPPLEMENTAIRES POUR COMPLETER SA SERIE B A HAUTEUR DE 22,3 M €

Communiqués de presse

6 novembre 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Communiqués de presse

6 novembre 2019

ACTICOR BIOTECH LEVE 7 M € SUPPLEMENTAIRES POUR COMPLETER SA SERIE B A HAUTEUR DE 22,3 M €

Communiqués de presse

5 novembre 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Communiqués de presse

5 novembre 2019

ACTICOR BIOTECH PARTENAIRE DU CONSORTIUM BOOSTER DEDIE A LA PRISE EN CHARGE ET AUX NOUVEAUX TRAITEMENTS DES ACCIDENTS VASCULAIRES CÉREBRAUX (AVC) EN SITUATION D’URGENCE

Communiqués de presse

5 novembre 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Communiqués de presse

5 novembre 2019

ACTICOR BIOTECH PARTENAIRE DU CONSORTIUM BOOSTER DEDIE A LA PRISE EN CHARGE ET AUX NOUVEAUX TRAITEMENTS DES ACCIDENTS VASCULAIRES CÉREBRAUX (AVC) EN SITUATION D’URGENCE

Communiqués de presse

5 novembre 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Communiqués de presse

5 novembre 2019

ACTICOR BIOTECH PARTENAIRE DU CONSORTIUM BOOSTER DEDIE A LA PRISE EN CHARGE ET AUX NOUVEAUX TRAITEMENTS DES ACCIDENTS VASCULAIRES CÉREBRAUX (AVC) EN SITUATION D’URGENCE

Communiqués de presse

21 août 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Communiqués de presse

21 août 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Communiqués de presse

21 août 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Communiqués de presse

21 août 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Communiqués de presse

21 août 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Communiqués de presse

21 août 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Communiqués de presse

14 juin 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Communiqués de presse

14 juin 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Communiqués de presse

14 juin 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Communiqués de presse

14 juin 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Communiqués de presse

14 juin 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Communiqués de presse

14 juin 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Communiqués de presse

25 avril 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Communiqués de presse

25 avril 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Communiqués de presse

25 avril 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Communiqués de presse

25 avril 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Communiqués de presse

25 avril 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Communiqués de presse

25 avril 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Communiqués de presse

5 février 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Communiqués de presse

5 février 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Communiqués de presse

5 février 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Communiqués de presse

5 février 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Communiqués de presse

5 février 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Communiqués de presse

5 février 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Communiqués de presse

4 janvier 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Communiqués de presse

4 janvier 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Communiqués de presse

4 janvier 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Communiqués de presse

4 janvier 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Communiqués de presse

4 janvier 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Communiqués de presse

4 janvier 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Communiqués de presse

20 décembre 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Communiqués de presse

20 décembre 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Communiqués de presse

20 décembre 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Communiqués de presse

20 décembre 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Communiqués de presse

20 décembre 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Communiqués de presse

20 décembre 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Communiqués de presse

17 octobre 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Communiqués de presse

17 octobre 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Communiqués de presse

17 octobre 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Communiqués de presse

17 octobre 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Communiqués de presse

17 octobre 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Communiqués de presse

17 octobre 2017

Communiqués de presse

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

ACTICOR BIOTECH INTEGRE LE 1ER FRENCH TECH 120

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH LEVE 7 M € SUPPLEMENTAIRES POUR COMPLETER SA SERIE B A HAUTEUR DE 22,3 M €

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH LEVE 7 M € SUPPLEMENTAIRES POUR COMPLETER SA SERIE B A HAUTEUR DE 22,3 M €

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

ACTICOR BIOTECH LEVE 7 M € SUPPLEMENTAIRES POUR COMPLETER SA SERIE B A HAUTEUR DE 22,3 M €

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTENAIRE DU CONSORTIUM BOOSTER DEDIE A LA PRISE EN CHARGE ET AUX NOUVEAUX TRAITEMENTS DES ACCIDENTS VASCULAIRES CÉREBRAUX (AVC) EN SITUATION D’URGENCE

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTENAIRE DU CONSORTIUM BOOSTER DEDIE A LA PRISE EN CHARGE ET AUX NOUVEAUX TRAITEMENTS DES ACCIDENTS VASCULAIRES CÉREBRAUX (AVC) EN SITUATION D’URGENCE

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

ACTICOR BIOTECH PARTENAIRE DU CONSORTIUM BOOSTER DEDIE A LA PRISE EN CHARGE ET AUX NOUVEAUX TRAITEMENTS DES ACCIDENTS VASCULAIRES CÉREBRAUX (AVC) EN SITUATION D’URGENCE

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

Acticor Biotech first-in-human clinical trial in healthy volunteers

S'abonner à l'alerte e-mail

Navigation

Nous contacter